<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866528</url>
  </required_header>
  <id_info>
    <org_study_id>111109</org_study_id>
    <nct_id>NCT00866528</nct_id>
  </id_info>
  <brief_title>Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be
      administered safely in combination. The Phase II part of the study will not be progressed as
      documented in Protocol Amendment 01.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2009</start_date>
  <completion_date type="Actual">October 25, 2012</completion_date>
  <primary_completion_date type="Actual">October 25, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: safety and tolerability (Serious adverse events, adverse events, dose-limiting toxicities, clinical laboratory data, vital signs, ECG, ECOG performance status)</measure>
    <time_frame>at least one cycle of treatment (3 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: paclitaxel and pazopanib pharmacokinetics</measure>
    <time_frame>Cycle 1 and Cycle 2 PK sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: clinical activity</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Lung Cancer, Non-Small Cell</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>oral pazopanib once daily (Phase I starting dose 800 mg)</description>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).</description>
    <arm_group_label>Phase I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  At least 18 years old

          -  Histologically- or cytologically-confirmed diagnosis of Stage IIIBwet (with confirmed
             malignant pleural effusion) or Stage IV NSCLC (or for Phase I only, advanced solid
             tumor for which there is no standard therapy or for whom paclitaxel is standard
             therapy).

          -  No prior systemic first-line therapy for advanced disease

          -  Measurable disease

          -  ECOG performance status of 0 or 1

          -  Life expectancy of at least 12 weeks.

          -  Able to swallow and retain oral medication

          -  Adequate organ system function (hematological, renal, and hepatic)

          -  Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR
             childbearing potential, and agrees to use adequate contraception

        Exclusion Criteria:

          -  Active malignancy or any malignancy in the 3 years prior to first dose of study drug
             other than NSCLC (or for Phase I, other than the primary solid tumor)

          -  CNS metastases or leptomeningeal carcinomatosis, except for asymptomatic, previously
             treated CNS metastases

          -  Clinically significant gastrointestinal abnormalities

          -  Prolongation of corrected QT interval (QTc) &gt; 480 msecs

          -  History of any one or more cardiovascular conditions within the past 6 months prior to
             randomization

          -  Poorly controlled hypertension

          -  History of cerebrovascular accident (including transient ischemic attacks), pulmonary
             embolism or untreated deep venous thrombosis (DVT) within the past 6 months

          -  Major surgery or trauma within 28 days or any non-healing wound, fracture, or ulcer

          -  Evidence of active bleeding or bleeding diathesis

          -  Recent hemoptysis

          -  Endobronchial lesions and/or lesions infiltrating major pulmonary vessels

          -  Serious and/or unstable pre-existing medical (e.g., uncontrolled infection),
             psychiatric, or other condition that could interfere with subject's safety, provision
             of informed consent, or compliance to study procedures

          -  Use of any prohibited medication

          -  Use of an investigational agent within 28 days or 5 half-lives, whichever is longer,
             prior to the first dose of study drug

          -  Ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is
             progressing in severity except alopecia

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to pazopanib, paclitaxel, and/or carboplatin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/111109?search=study&amp;study_ids=111109#rs</url>
    <description>Results for study 111109 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>NSCLC</keyword>
  <keyword>pazopanib</keyword>
  <keyword>Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>GW786034</keyword>
  <keyword>Metastatic Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

